Low miR-10b-3p associated with sorafenib resistance in hepatocellular carcinoma
Journal
British journal of cancer
Journal Volume
126
Journal Issue
12
Pages
1806
Date Issued
2022-06-11
Author(s)
Chen, Pai-Sheng
Lee, Bin-Shyun
Ling, Andrew
Abstract
Sorafenib is one of the standard first-line therapies for advanced hepatocellular carcinoma (HCC). Unfortunately, there are currently no appropriate biomarkers to predict the clinical efficacy of sorafenib in HCC patients. MicroRNAs (miRNAs) have been studied for their biological functions and clinical applications in human cancers.
Subjects
DOWN-REGULATION; MICRORNA; CELLS; SERUM; BIOMARKER; CONTRIBUTES; PROGRESSION; INHIBITION; EXPRESSION; DIAGNOSIS
SDGs
Publisher
SPRINGERNATURE
Type
journal article